Title: Nanodrug potential in cancer therapy: efficacy/toxicity studies in cancer cells

Authors: Alessandra Pagano; Stéphane Honoré; Marie-Anne Estève; Diane Braguer

Addresses: Aix-Marseille Univ, CRO2, 13385 Marseille, France; INSERM UMR911, 13385 Marseille, France. ' Aix-Marseille Univ, CRO2, 13385 Marseille, France; INSERM UMR911, 13385 Marseille, France; Assistance Publique-Hôpitaux de Marseille, 13385 Marseille, France. ' Aix-Marseille Univ, CRO2, 13385 Marseille, France; INSERM UMR911, 13385 Marseille, France; Assistance Publique-Hôpitaux de Marseille, 13385 Marseille, France. ' Aix-Marseille Univ, CRO2, 13385 Marseille, France; INSERM UMR911, 13385 Marseille, France; Assistance Publique-Hôpitaux de Marseille, 13385 Marseille, France

Abstract: The interest of nanotechnology to find a more effective approach for drug delivery is growing fast. Nanoparticles as drug vehicles potentially improve the pharmacokinetic and pharmacodynamic properties of various types of drugs, and provide a tool to visualise molecules and tumour target cells that otherwise cannot be detected through conventional imaging. However, there are many aspects of nanoparticle formulation, characterisation and their effect on delivery of drugs and therapeutics that remain to be explored. This review summarises the main characteristics of nanoparticles for drug delivery in cancer treatment, and describes an experimental approach for evaluating efficacy and toxicity of nanocarriers in cancer cells.

Keywords: nanodrugs; nanocarriers; nanotoxicology; drug delivery; cancer treatment; tumour cells; nanomedicine; nanodiamond; microtubule; paclitaxel; cancer cells; nanotechnology; nanoparticles; therapeutics.

DOI: 10.1504/IJNT.2012.045352

International Journal of Nanotechnology, 2012 Vol.9 No.3/4/5/6/7, pp.502 - 516

Received: 08 May 2021
Accepted: 12 May 2021

Published online: 06 Feb 2012 *

Full-text access for editors Access for subscribers Purchase this article Comment on this article